The article you site says the following:
"With Rettsyndrome.org stepping in to foot the bill on this one, Anavex shareholders are essentially being let off the hook for what would have been a dilutive raise.
The company has run up to the tune of 4% on the release, which we think is a market oversight. The avoidance of dilution alone should be enough to push the gains into double digits, but beyond that, that the company has a fully funded phase 2 trial about to kick off should add equal or further value to the run."
News 
Market Data 
Discover 
